CN112795995A - Dry spinning method for medical hemostatic fiber and manufacturing method thereof - Google Patents
Dry spinning method for medical hemostatic fiber and manufacturing method thereof Download PDFInfo
- Publication number
- CN112795995A CN112795995A CN202110145665.1A CN202110145665A CN112795995A CN 112795995 A CN112795995 A CN 112795995A CN 202110145665 A CN202110145665 A CN 202110145665A CN 112795995 A CN112795995 A CN 112795995A
- Authority
- CN
- China
- Prior art keywords
- parts
- spinning
- medical hemostatic
- dry spinning
- hemostatic fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 44
- 238000000578 dry spinning Methods 0.000 title claims abstract description 42
- 239000000835 fiber Substances 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 229920001436 collagen Polymers 0.000 claims abstract description 25
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 24
- 229920000805 Polyaspartic acid Polymers 0.000 claims abstract description 22
- 108010064470 polyaspartate Proteins 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 17
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 17
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 17
- 229930006000 Sucrose Natural products 0.000 claims abstract description 17
- 239000012153 distilled water Substances 0.000 claims abstract description 17
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 17
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 17
- 239000005720 sucrose Substances 0.000 claims abstract description 17
- -1 sucrose ester Chemical class 0.000 claims abstract description 17
- 238000009987 spinning Methods 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 20
- 210000002435 tendon Anatomy 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 238000009210 therapy by ultrasound Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 7
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 7
- 229920000153 Povidone-iodine Polymers 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 229960003639 laurocapram Drugs 0.000 claims description 7
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 229960001621 povidone-iodine Drugs 0.000 claims description 7
- 239000009637 wintergreen oil Substances 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000007872 degassing Methods 0.000 claims 1
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F4/00—Monocomponent artificial filaments or the like of proteins; Manufacture thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/102—Collagen
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/04—Dry spinning methods
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
- D01F1/103—Agents inhibiting growth of microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to the technical field of hemostatic fibers, in particular to dry spinning of medical hemostatic fibers, which comprises the following components in parts by weight: 60-80 parts of collagen, 2.5-4 parts of sucrose ester, 1-3 parts of glucuronic acid, 6-11 parts of hydroxyethyl cellulose, 1-3 parts of polyaspartic acid, 0.5-1.2 parts of antibacterial agent and 28-40 parts of distilled water.
Description
Technical Field
The invention relates to the technical field of hemostatic fibers, in particular to dry spinning of medical hemostatic fibers and a manufacturing method thereof.
Background
Bleeding from the wound surface is a common problem in wound emergency and common surgical operations. Excessive blood loss can endanger life, increase the chance of infection and reduce the success rate of the operation. Thus, appropriate hemostatic means can significantly shorten the time of surgery, and are important for trauma or post-operative recovery. There are many hemostasis methods, and according to the bleeding part, the size of the operation cavity and the compatibility with the organism, the blood coagulation function and the economic condition of the patient, the mechanical hemostasis method such as suture, ligation, electrocoagulation and the like or other hemostasis materials such as tourniquets, bandages, medical sponges, cotton swabs, gauzes and the like are commonly used clinically. However, conventional hemostatic materials do not have a good hemostatic effect in the face of complicated wound sites and extensive diffuse bleeding. The ideal hemostatic material has the advantages of rapid hemostasis, no infection risk, safety, no stimulation, no influence on tissue healing, difficult dissolution, rapid degradation and controllability. In recent years, with the intensive research on medical biological hemostatic materials, a large number of polymer materials, such as: collagen, silk fibroin, soybean protein, wheat protein, hyaluronic acid, polycaprolactone, gelatin, chitosan, cellulose, polylactic acid, polyethylene glycol, nano microcrystalline cellulose, hydrogel and the like, has low immunogenicity, good tensile strength, strong hemostatic function, good biodegradability, safety, no toxicity and no irritation, and is widely used for manufacturing various hemostatic sponge products. However, for irregular wounds or extensive diffuse bleeding during surgery, the hemostatic sponge cannot deeply contact and engage with the anastomotic wound, and the clinical application has great limitation.
Therefore, we propose dry spinning of medical hemostatic fiber and a method for manufacturing the same to solve the above problems.
Disclosure of Invention
The invention aims to solve the defects in the prior art and provides dry spinning of medical hemostatic fibers and a manufacturing method thereof.
The dry spinning method of the medical hemostatic fiber comprises the following components in parts by weight: 60-80 parts of collagen, 2.5-4 parts of sucrose ester, 1-3 parts of glucuronic acid, 6-11 parts of hydroxyethyl cellulose, 1-3 parts of polyaspartic acid, 0.5-1.2 parts of an antibacterial agent and 28-40 parts of distilled water.
Preferably, the composition comprises the following components in parts by weight: 70 parts of collagen, 3.3 parts of sucrose ester, 2 parts of glucuronic acid, 8 parts of hydroxyethyl cellulose, 2 parts of polyaspartic acid, 0.8 part of an antibacterial agent and 35 parts of distilled water.
Preferably, the antibacterial agent is a mixture of laurocapram, povidone iodine and wintergreen oil in a mass ratio of 2:1: 2.5.
Preferably, the collagen is extracted from any one of pig tendon, cattle tendon and silk.
Preferably, the relative molecular weight of the polyaspartic acid is 3000-4000.
Preferably, the manufacturing method of the dry spinning of the medical hemostatic fiber comprises the following steps:
s1, adding collagen, sucrose ester, glucuronic acid, hydroxyethyl cellulose, polyaspartic acid, an antibacterial agent and distilled water into a stirrer, stirring for 40-60min at the stirring temperature of 60-80 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
Preferably, the dry spinning process parameters are as follows:
spinning temperature: 85-95 ℃;
the spinning pressure is 2.5-4 MPa;
the spinning speed is 180-;
the spinning speed is 220 and 280 m/min;
the temperature of a spinning window is 88-95 ℃;
the temperature of the air inlet is 120 ℃ and 160 ℃;
the inlet air volume is 4-6m3/min；
The cutting length is 45-50 mm.
Preferably, in S1, the specific operation mode of the defoaming treatment process is to perform ultrasonic treatment on the mixed solution in a vacuum environment, and the ultrasonic treatment time is 5-15 min.
Preferably, in S2, ethylene oxide gas is used for sterilization.
The invention has the beneficial effects that: the dry spinning method provided by the invention is simple in preparation method, the adopted raw materials are degradable materials, the biocompatibility is good, adverse reactions are not easy to generate, the polyaspartic acid has certain water absorption performance, and can be absorbed by the dry spinning when a small amount of body fluid seeps from the vicinity of a wound, so that the wound can be conveniently recovered, the dry spinning strength can be improved through the glucuronic acid, and the glucuronic acid also has a certain sterilization effect, so that the breeding of bacteria at the wound is prevented, and the recovery of the wound is facilitated.
Detailed Description
The present invention will be further illustrated with reference to the following specific examples.
In example 1, the dry spinning of the medical hemostatic fiber comprises the following components in parts by weight: 80 parts of collagen, 4 parts of sucrose ester, 3 parts of glucuronic acid, 11 parts of hydroxyethyl cellulose, 3 parts of polyaspartic acid, 1.2 parts of an antibacterial agent and 40 parts of distilled water.
Further, the antibacterial agent is a mixture of laurocapram, povidone iodine and wintergreen oil in a mass ratio of 2:1: 2.5.
Further, the collagen is extracted from any one of pig tendon, cattle tendon and silk.
Further, the relative molecular weight of polyaspartic acid is 3000-4000.
Further, the manufacturing method of the dry spinning of the medical hemostatic fiber comprises the following steps:
s1, adding collagen, sucrose ester, glucuronic acid, hydroxyethyl cellulose, polyaspartic acid, an antibacterial agent and distilled water into a stirrer, stirring for 40min at the stirring temperature of 60 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
Further, the dry spinning process parameters are as follows:
spinning temperature: 85 ℃;
the spinning pressure is 2.5 MPa;
the spinning speed is 180 m/min;
the spinning speed is 220 m/min;
the temperature of a spinning window is 88 ℃;
the temperature of an air inlet is 120 ℃;
inlet air volume of 4m3/min；
The cut length was 45 mm.
Further, in S1, the specific operation mode of the defoaming treatment process is to perform ultrasonic treatment on the mixed solution in a vacuum environment, and the ultrasonic treatment time is 5 min.
Further, in S2, ethylene oxide gas is used for sterilization during the sterilization process.
In example 2, the dry spinning of the medical hemostatic fiber comprises the following components in parts by weight: 80 parts of collagen, 4 parts of sucrose ester, 3 parts of glucuronic acid, 11 parts of hydroxyethyl cellulose, 3 parts of polyaspartic acid, 1.2 parts of an antibacterial agent and 40 parts of distilled water.
Further, the antibacterial agent is a mixture of laurocapram, povidone iodine and wintergreen oil in a mass ratio of 2:1: 2.5.
Further, the collagen is extracted from any one of pig tendon, cattle tendon and silk.
Further, the relative molecular weight of polyaspartic acid is 3000-4000.
Further, the manufacturing method of the dry spinning of the medical hemostatic fiber comprises the following steps:
s1, adding collagen, sucrose ester, glucuronic acid, hydroxyethyl cellulose, polyaspartic acid, an antibacterial agent and distilled water into a stirrer, stirring for 60min at the stirring temperature of 80 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
Further, the dry spinning process parameters are as follows:
spinning temperature: 95 ℃;
the spinning pressure is 4 MPa;
the spinning speed is 240 m/min;
the spinning speed is 280 m/min;
the temperature of a spinning window is 95 ℃;
the temperature of an air inlet is 160 ℃;
inlet air volume of 6m3/min；
The cut length was 50 mm.
Further, in S1, the specific operation manner of the defoaming treatment process is to perform ultrasonic treatment on the mixed solution in a vacuum environment, and the ultrasonic treatment time is 15 min.
Further, in S2, ethylene oxide gas is used for sterilization during the sterilization process.
In example 3, the dry spinning of the medical hemostatic fiber comprises the following components in parts by weight: 70 parts of collagen, 3.3 parts of sucrose ester, 2 parts of glucuronic acid, 8 parts of hydroxyethyl cellulose, 2 parts of polyaspartic acid, 0.8 part of an antibacterial agent and 35 parts of distilled water.
Further, the antibacterial agent is a mixture of laurocapram, povidone iodine and wintergreen oil in a mass ratio of 2:1: 2.5.
Further, the collagen is extracted from any one of pig tendon, cattle tendon and silk.
Further, the relative molecular weight of polyaspartic acid is 3000-4000.
Further, the manufacturing method of the dry spinning of the medical hemostatic fiber comprises the following steps:
s1, adding collagen, sucrose ester, glucuronic acid, hydroxyethyl cellulose, polyaspartic acid, an antibacterial agent and distilled water into a stirrer, stirring for 50min at the stirring temperature of 70 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
Further, the dry spinning process parameters are as follows:
spinning temperature: 90 ℃;
the spinning pressure is 3 MPa;
the spinning speed is 220 m/min;
the spinning speed is 260 m/min;
the temperature of a spinning window is 92 ℃;
the temperature of an air inlet is 140 ℃;
inlet air volume of 5m3/min；
The cut length was 48 mm.
Further, in S1, the specific operation mode of the defoaming treatment process is to perform ultrasonic treatment on the mixed solution in a vacuum environment, and the ultrasonic treatment time is 10 min.
Further, in S2, ethylene oxide gas is used for sterilization during the sterilization process.
In comparative example 1, in example 3, the dry spinning method of the medical hemostatic fiber comprises the following components in parts by weight: 70 parts of collagen, 3.3 parts of sucrose ester, 8 parts of hydroxyethyl cellulose, 2 parts of polyaspartic acid, 0.8 part of antibacterial agent and 35 parts of distilled water.
Further, the antibacterial agent is a mixture of laurocapram, povidone iodine and wintergreen oil in a mass ratio of 2:1: 2.5.
Further, the collagen is extracted from any one of pig tendon, cattle tendon and silk.
Further, the relative molecular weight of polyaspartic acid is 3000-4000.
Further, the manufacturing method of the dry spinning of the medical hemostatic fiber comprises the following steps:
s1, adding collagen, sucrose ester, hydroxyethyl cellulose, polyaspartic acid, an antibacterial agent and distilled water into a stirrer, stirring for 50min at the stirring temperature of 70 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
Further, the dry spinning process parameters are as follows:
spinning temperature: 90 ℃;
the spinning pressure is 3 MPa;
the spinning speed is 220 m/min;
the spinning speed is 260 m/min;
the temperature of a spinning window is 92 ℃;
the temperature of an air inlet is 140 ℃;
inlet air volume of 5m3/min；
The cut length was 48 mm.
Further, in S1, the specific operation mode of the defoaming treatment process is to perform ultrasonic treatment on the mixed solution in a vacuum environment, and the ultrasonic treatment time is 10 min.
Further, in S2, ethylene oxide gas is used for sterilization during the sterilization process.
In comparative example 2, in example 3, the dry spinning method of the medical hemostatic fiber comprises the following components in parts by weight: 70 parts of collagen, 3.3 parts of sucrose ester, 2 parts of glucuronic acid, 8 parts of hydroxyethyl cellulose, 0.8 part of antibacterial agent and 35 parts of distilled water.
Further, the antibacterial agent is a mixture of laurocapram, povidone iodine and wintergreen oil in a mass ratio of 2:1: 2.5.
Further, the collagen is extracted from any one of pig tendon, cattle tendon and silk.
Further, the manufacturing method of the dry spinning of the medical hemostatic fiber comprises the following steps:
s1, adding collagen, sucrose ester, glucuronic acid, hydroxyethyl cellulose, an antibacterial agent and distilled water into a stirrer, stirring for 50min at the stirring temperature of 70 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
Further, the dry spinning process parameters are as follows:
spinning temperature: 90 ℃;
the spinning pressure is 3 MPa;
the spinning speed is 220 m/min;
the spinning speed is 260 m/min;
the temperature of a spinning window is 92 ℃;
the temperature of an air inlet is 140 ℃;
inlet air volume of 5m3/min；
The cut length was 48 mm.
Further, in S1, the specific operation mode of the defoaming treatment process is to perform ultrasonic treatment on the mixed solution in a vacuum environment, and the ultrasonic treatment time is 10 min.
Further, in S2, ethylene oxide gas is used for sterilization during the sterilization process.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (9)
1. The dry spinning method of the medical hemostatic fiber is characterized by comprising the following components in parts by weight: 60-80 parts of collagen, 2.5-4 parts of sucrose ester, 1-3 parts of glucuronic acid, 6-11 parts of hydroxyethyl cellulose, 1-3 parts of polyaspartic acid, 0.5-1.2 parts of an antibacterial agent and 28-40 parts of distilled water.
2. The dry spinning method of medical hemostatic fiber according to claim 1, characterized by comprising the following components in parts by weight: 70 parts of collagen, 3.3 parts of sucrose ester, 2 parts of glucuronic acid, 8 parts of hydroxyethyl cellulose, 2 parts of polyaspartic acid, 0.8 part of an antibacterial agent and 35 parts of distilled water.
3. The dry spinning of medical hemostatic fiber according to claim 1, wherein the antibacterial agent is a mixture of laurocapram, povidone iodine, and wintergreen oil at a mass ratio of 2:1: 2.5.
4. The dry-spun medical hemostatic fiber according to claim 1, wherein the collagen is extracted from any one of pig tendon, cow tendon, and silk.
5. The dry-spun medical hemostatic fiber according to claim 1, wherein the relative molecular weight of the polyaspartic acid is 3000-4000.
6. The method for manufacturing the medical hemostatic fiber by dry spinning according to claim 1, comprising the steps of:
s1, adding collagen, sucrose ester, glucuronic acid, hydroxyethyl cellulose, polyaspartic acid, an antibacterial agent and distilled water into a stirrer, stirring for 40-60min at the stirring temperature of 60-80 ℃, and filtering and defoaming after stirring;
and S2, performing dry spinning after defoaming, drying and forming, collecting, sterilizing and packaging to obtain the medical hemostatic fiber.
7. The dry spinning manufacturing method of medical hemostatic fiber according to claim 6, characterized in that the dry spinning process parameters are:
spinning temperature: 85-95 ℃;
the spinning pressure is 2.5-4 MPa;
the spinning speed is 180-;
the spinning speed is 220 and 280 m/min;
the temperature of a spinning window is 88-95 ℃;
the temperature of the air inlet is 120 ℃ and 160 ℃;
the inlet air volume is 4-6m3/min；
The cutting length is 45-50 mm.
8. The method for manufacturing a medical hemostatic fiber by dry spinning according to claim 6, wherein the step of degassing in S1 is performed by subjecting the mixed solution to ultrasonic treatment in a vacuum environment for 5-15 min.
9. The method for manufacturing dry spinning of medical hemostatic fiber according to claim 6, wherein in the step S2, ethylene oxide gas is used for sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110145665.1A CN112795995A (en) | 2021-02-03 | 2021-02-03 | Dry spinning method for medical hemostatic fiber and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110145665.1A CN112795995A (en) | 2021-02-03 | 2021-02-03 | Dry spinning method for medical hemostatic fiber and manufacturing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112795995A true CN112795995A (en) | 2021-05-14 |
Family
ID=75813776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110145665.1A Pending CN112795995A (en) | 2021-02-03 | 2021-02-03 | Dry spinning method for medical hemostatic fiber and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112795995A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0463887A2 (en) * | 1990-06-29 | 1992-01-02 | Koken Company Limited | Collagen fiber hemostatic material and method of producing the same |
| JPH0835193A (en) * | 1994-07-19 | 1996-02-06 | Mitsubishi Rayon Co Ltd | Production of collagen fiber nonwoven fabric sheet |
| CN1270240A (en) * | 2000-04-21 | 2000-10-18 | 中国石油化工集团公司 | Staltic fibre and its manufacture method |
| US6361551B1 (en) * | 1998-12-11 | 2002-03-26 | C. R. Bard, Inc. | Collagen hemostatic fibers |
| US20110237539A1 (en) * | 2010-03-26 | 2011-09-29 | Taiwan Textile Research Institute | Spinning Solution and Method for Manufacturing Biomaterial Fibers |
| CN103230617A (en) * | 2013-04-24 | 2013-08-07 | 四川大学 | Collagen/chitosan micro-nano fiber composite hemostatic membrane material and preparation method thereof |
| CN105770962A (en) * | 2016-05-06 | 2016-07-20 | 王泽陆 | Degradable antibacterial hemostatic fiber pad and preparation method thereof |
| JP2017061757A (en) * | 2015-09-25 | 2017-03-30 | 兵庫県 | Method for producing collagen fiber |
| CN110433325A (en) * | 2019-07-26 | 2019-11-12 | 杭州中科润德生物技术发展有限公司 | A kind of protide high polymer nanometer fiber hemostatic material and its preparation method and application |
-
2021
- 2021-02-03 CN CN202110145665.1A patent/CN112795995A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0463887A2 (en) * | 1990-06-29 | 1992-01-02 | Koken Company Limited | Collagen fiber hemostatic material and method of producing the same |
| JPH0835193A (en) * | 1994-07-19 | 1996-02-06 | Mitsubishi Rayon Co Ltd | Production of collagen fiber nonwoven fabric sheet |
| US6361551B1 (en) * | 1998-12-11 | 2002-03-26 | C. R. Bard, Inc. | Collagen hemostatic fibers |
| CN1270240A (en) * | 2000-04-21 | 2000-10-18 | 中国石油化工集团公司 | Staltic fibre and its manufacture method |
| US20110237539A1 (en) * | 2010-03-26 | 2011-09-29 | Taiwan Textile Research Institute | Spinning Solution and Method for Manufacturing Biomaterial Fibers |
| CN103230617A (en) * | 2013-04-24 | 2013-08-07 | 四川大学 | Collagen/chitosan micro-nano fiber composite hemostatic membrane material and preparation method thereof |
| JP2017061757A (en) * | 2015-09-25 | 2017-03-30 | 兵庫県 | Method for producing collagen fiber |
| CN105770962A (en) * | 2016-05-06 | 2016-07-20 | 王泽陆 | Degradable antibacterial hemostatic fiber pad and preparation method thereof |
| CN110433325A (en) * | 2019-07-26 | 2019-11-12 | 杭州中科润德生物技术发展有限公司 | A kind of protide high polymer nanometer fiber hemostatic material and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| 刘宜群编著: "《痤疮》", 31 January 2005 * |
| 温辉梁主编: "《生物化工产品生产技术》", 31 December 2004 * |
| 王兴国主编: "《油料科学原理》", 31 August 2017 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5075811B2 (en) | Method for producing antimicrobial wound dressing and use thereof | |
| CN101455857B (en) | Biocompatibility modified starch sponges | |
| US3988411A (en) | Spinning and shaping poly-(N-acetyl-D-glucosamine) | |
| US4074713A (en) | Poly(N-acetyl-D-glucosamine) products | |
| CN107812230B (en) | Dismantling-free antibacterial operation suture line and preparation method thereof | |
| RU2682336C2 (en) | Degradable haemostat composition | |
| CN107551312B (en) | Flocculent collagen hemostatic fiber and preparation method thereof | |
| US3989535A (en) | Solution of poly(N-acetyl-D-glucosamine) | |
| CN112007200B (en) | Antibacterial repair-promoting hemostatic anti-adhesion membrane and preparation method thereof | |
| CN111467560B (en) | Medical hemostatic dressing, preparation method and application thereof | |
| CN106975098B (en) | Composite polysaccharide hemostatic composition and preparation method and application thereof | |
| US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
| CN111991611B (en) | Self-repairing hemostatic sponge capable of being adhered and preparation method thereof | |
| CN109260507A (en) | A kind of high liquid-absorbing fibroin albumen haemostatic membrane and preparation method thereof | |
| CN109157672A (en) | A kind of preparation method of fibroin-small peptide blood coagulation microballoon | |
| CN112795995A (en) | Dry spinning method for medical hemostatic fiber and manufacturing method thereof | |
| CN108853563B (en) | Preparation method of absorbable suture line | |
| JP3520511B2 (en) | Method for producing wound-absorbent covering protective material using cellulose sponge | |
| CN112007202B (en) | Adhesive healing-promoting hemostatic sponge and preparation method thereof | |
| JP4875804B2 (en) | Hemostatic material | |
| EP1269951B1 (en) | Absorbable protective coatings for wound with the use of cellulose sponge and process for producing the same | |
| CN111939315B (en) | Adherable healing-promoting hemostatic membrane and preparation method thereof | |
| CN110538344B (en) | Medical degradable hemostatic material and preparation method thereof | |
| CN107715167A (en) | Chitosan-based hemostatic paste and preparation method as bone wax substitute | |
| JP4955156B2 (en) | Hemostatic material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |